title: [Sirolimus-eluting stent for in-stent restenosis treatment: single center results in an unselected study population].
abstract: BACKGROUND
  Sirolimus-eluting stents have already proved to be efficient in the prevention of restenosis in de novo lesions and have been already proposed as a potential treatment of in-stent restenosis. In the present study, we evaluated the effectiveness of sirolimus-eluting stent implantation in unselected patients with in-stent restenosis.
  
  
  METHODS
  Fifty consecutive patients (59 lesions) were treated with sirolimus-eluting stents for instent restenosis. The incidence of major adverse cardiovascular events and restenosis was evaluated at 1-year clinical and angiographic follow-up.
  
  
  RESULTS
  At baseline, 54% of the lesions were complex (46% proliferative and 8% total occlusions). Small vessel size (< or = 2.5 mm) was present in 30%, a long lesion (> 20 mm) in 25%, and diabetes in 42% of the patients. The angiographic follow-up was obtained in 47 patients (55 lesions). Restenosis was observed in 13% of the lesions. At the 1-year follow-up, the incidence of major adverse cardiovascular events was 16% (4% acute myocardial infarction, 12% target lesion revascularization).
  
  
  CONCLUSIONS
  This study confirms the efficacy of sirolimus-eluting stents for the treatment of instent restenosis in an unselected population of consecutive patients at high risk of restenosis and with a broad range of morphological lesion patterns.
authors.affiliation: U.O. di Cardiologia, Ospedale Misericordia e Dolce, Prato. francesco.mail@tele2.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Bellandi
authors.forename: Anna
authors.initials: A
authors.lastname: Toso
authors.forename: Mauro
authors.initials: M
authors.lastname: Maioli
authors.forename: Mario
authors.initials: M
authors.lastname: Leoncini
authors.forename: Roberto Piero
authors.initials: RP
authors.lastname: Dabizzi
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control / Q000628:therapy*; D016503:Drug Delivery Systems; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus